EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers

Bo Ding, Stephanie Chen, Eleni Rapsomaniki, Anna Quinton, William Cook, Helen K Reddel, Alberto Papi, NOVELTY Scientific Community, NOVELTY study investigators

The Journal of Allergy and Clinical Immunology: In Practice · 2024-04 · 12 (4) · 970-982

DOI: 10.1016/j.jaip.2023.12.021 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-04. Verfasst von Bo Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Bo.Ding@astrazeneca.com. Hauptthemen laut MEDLINE: Asthma, Eosinophilia, Hypersensitivity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Many patients with asthma have type-2 airway inflammation, identified by the presence of biomarkers, including history of allergy, high blood eosinophil (EOS) count, and high fractional exhaled nitric oxide levels. OBJECTIVE: To assess disease burden in relation to type-2 inflammatory biomarker status (history of allergy, blood EOS count, and fractional exhaled nitric oxide level) in patients with uncontrolled and controlled severe asthma in the NOVEL observational longiTudinal studY (NOVELTY) (NCT02760329). METHODS: Asthma diagnosis and severity were physician-reported. Control was defined using Asthma Control Test score (uncontrolled

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaEosinophiliaHypersensitivityHumansBiomarkersEosinophilsLongitudinal StudiesNitric Oxide

Stichwörter der Autor:innen

AllergyAsthmaDisease burdenEosinophilExacerbationsFractional exhaled nitric oxideHealth care resource utilizationHealth statusSymptom controlType-2 inflammatory biomarkers

Substanzen

BiomarkersNitric Oxide

Autor:innen und Institutionen

  • BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Bo.Ding@astrazeneca.com.
  • BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
  • Real World Data Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
  • Global Health Economics and Payer Evidence, AstraZeneca, Cambridge, United Kingdom.
  • The Woolcock Institute of Medical Research and Macquarie University, Sydney, New South Wales, Australia.
  • Respiratory Medicine Unit, Department of Translational Medicine, Università di Ferrara, Ferrara, Italy.

Förderung

  • AstraZeneca

Zitieren

APA

Ding, B., Chen, S., Rapsomaniki, E., Quinton, A., Cook, W., Reddel, H. K., Papi, A., NOVELTY Scientific Community, & NOVELTY study investigators (2024). Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers. The Journal of Allergy and Clinical Immunology: In Practice, 12(4), 970-982. https://doi.org/10.1016/j.jaip.2023.12.021

Vancouver

Ding B, Chen S, Rapsomaniki E, Quinton A, Cook W, Reddel HK, et al. Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(4):970-982. doi:10.1016/j.jaip.2023.12.021

BibTeX
@article{Ding2024,
  author = {Ding, Bo and Chen, Stephanie and Rapsomaniki, Eleni and Quinton, Anna and Cook, William and Reddel, Helen K and Papi, Alberto and NOVELTY Scientific Community, NOVELTY Scientific Community and NOVELTY study investigators, NOVELTY study investigators},
  title = {Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {970--982},
  doi = {10.1016/j.jaip.2023.12.021}
}
Kostenlos starten →